Sanofi to Acquire Translate Bio for ~$3.2B

Shots:

  • Sanofi to acquire all outstanding shares of Translate Bio for $38.00/share in cash making a total equity value of ~$3.2B with a premium of 30.4% to Translate Bio’s one day prior closing price of $29.15. The acquisition is expected to complete in the Q3’21
  • The acquisition will utilize mRNA technology to further accelerates Sanofi’s licensed programs to develop transformative therapies & vaccines
  • In Jun’18, Sanofi entered into a license agreement with Translate Bio to develop mRNA vaccines & further expanded in 2020 for infectious diseases. Additionally, the recent acquisition of Tidal has expanded Sanofi’s mRNA research capabilities in both immuno-oncology and inflammatory diseases

Click here to  to read full press release/ article | Ref: GlobeNewswire | Image: Medcity News

The post Sanofi to Acquire Translate Bio for ~$3.2B first appeared on PharmaShots.